CytoGenix Antibacterial Discovery Published In Medical Research Journal

CytoGenix Inc. (OTCBB:CYGX) announced today that a manuscript reporting the results of studies conducted by Dr. Yin Chen, Vice President of R & D, and Dr. Xin-Xing Tan, Senior Scientist, was accepted for publication in the respected scientific journal Biochemistry. This paper reports the successful use of the company's proprietary cell-based DNA screening and targeting method to discover novel antibacterial compounds and potential drug-susceptible molecular targets.

Drs. Chen and Tan's paper, titled "A Novel Genomic Approach Identifies Bacterial DNA-Dependent RNA Polymerase as the Target of an Antibacterial Oligodeoxynucleotide, RBL1," will be published in an upcoming issue of the American Chemical Society's journal Biochemistry. "The purpose of Biochemistry is to publish the results of original research that contribute significantly to the understanding of the mechanism of biological phenomena in terms of molecular structure and/or function. Biochemistry investigates the rapidly changing arena where chemistry, biochemistry and molecular and cell biology interrelate."

Dr. Malcolm Skolnick, chairman/CEO, stated, "Our peers in the international medical research community continue to recognize and validate our scientific advances. This latest publication in this prestigious journal represents an important step in the application of our technology to the treatment of disease. Application of genetic techniques in disease control is the future of medicine and our mission at CytoGenix is to bring this technology from the laboratory to the clinic."

"Following the success of our compounds against Escherichia Coli to prevent sepsis in animal experiments, this discovery is the basis for development of antibacterial compounds targeting highly antibiotic-resistant strains of Staphylococcus and Streptococcus bacteria," adds Dr. Skolnick.